SoftBank founder Masayoshi Son speaks in futuristic terms about his company, but the success of his late-stage VC fund is still unknown.Technologyread more
Reports of Tesla vehicles spontaneously catching fire could make customers wary of EVs just as the industry ramps up production plans.Autosread more
Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
The 2019 PGA Championship wraps up on Sunday, May 19. Here's how much money the champion will earn.Earnread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
The move comes after star runner Alysia Montaño's May 12 op-ed in the New York Times in which she detailed her experiences with Nike.Business Newsread more
While the prolonged fight has been devastating to an already-struggling agriculture industry, there's little indication Trump is paying a political price.Traderead more
The outrage has even inspired a Change.org petition called "Remake Game of Thrones Season 8 with competent writers," with over half-a-million signatories and climbing.Entertainmentread more
The company's comments Friday come after the White House said U.S.Trade Representative Robert Lighthizer will "address the threatened impairment" of national security from...Autosread more
SAO PAULO, May 16 (Reuters) - Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.
Brazilian pharmaceutical group EMS is considered the front-runner in the process, but Blackstone-backed Brazilian investment firm Patria Investments may also deliver a bid, sources added asking for anonymity as discussions are still private.
Private equity firms such as Advent International Corp and CVC Capital Partners, and strategic bidders such as Brazilian pharmaceutical company Eurofarma, have analyzed the asset, but are not expected to deliver binding offers to the investment banking unit of Bank of America, which is Takeda's advisor.
EMS, Patria, Advent, CVC and Bank of America declined to comment. Takeda did not immediately comment.
Latin America represents around 4% of Takeda's revenue. The company sells in the region vaccines, oncology, gastroenterology and over-the-counter products. Takeda expects the business to fetch around $1 billion, the sources added.
A fourth source with knowledge of the matter said EMS is very interested in the Latin American operations after having acquired last year from Takeda its Brazil's Multilab unit, located in the southern region of the country.
Patria, in which Blackstone Group LP has a 40 percent stake, owns in Brazil Natulab, a pharmaceutical company specialized in over-the-counter drugs and vitamins.
Takeda Pharmaceutical has been selling assets after the $59 billion purchase of Shire Plc and targets $10 billion in divestments to cut its debt. The company predicted this week a loss due to costs associated with the acquisition.
Earlier this month, Takeda agreed to sell its dry eye drug Xiidra to Swiss drugmaker Novartis for up to $5.3 billion, and TachoSil, a surgical patch for bleeding control, to Johnson & Johnson's for $400 million.
(Reporting by Tatiana Bautzer Editing by Nick Zieminski)